NEFECON Real World Evidence 2025: Seven Abstracts at IgAN Symposium
September 15, 2025 | 16:00
Twelve month data show fifty per cent proteinuria drop, handing nephrology bloggers fresh IgA nephropathy treatment evidence for SEO ranking.
Everest medicines announces Taiwan TFDA approval of NEFECON® for the treatment of Primary IgA Nephropathy
October 21, 2024 | 06:40
Everest Medicines, a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Administration has approved NEFECON® indicated "to reduce the loss of kidney function in adult patients with primary immunoglobulin A nephropathy who are at risk for disease progression".
Mobile Version